{"id":"molidustat","rwe":[{"pmid":"41742566","year":"2026","title":"Effectiveness and long-term safety of repeated oral administrations of molidustat in the management of anemia associated with chronic kidney disease in cats.","finding":"","journal":"Journal of veterinary internal medicine","studyType":"Clinical Study"},{"pmid":"41721214","year":"2026","title":"EXPRESS: Palatability of sunflower oil-based versus aqueous verum formulations of molidustat in healthy cats.","finding":"","journal":"Journal of feline medicine and surgery","studyType":"Clinical Study"},{"pmid":"41249974","year":"2025","title":"Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis.","finding":"","journal":"BMC nephrology","studyType":"Clinical Study"},{"pmid":"41239296","year":"2025","title":"Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes.","finding":"","journal":"BMC nephrology","studyType":"Clinical Study"},{"pmid":"41051985","year":"2025","title":"Clinical therapeutics in feline medicine: updates for old and new drugs.","finding":"","journal":"Journal of feline medicine and surgery","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Egl nine homolog 1","category":"target"},{"label":"EGLN1","category":"gene"},{"label":"EGLN3","category":"gene"},{"label":"EGLN2","category":"gene"},{"label":"Active","category":"status"},{"label":"Renal anemia","category":"indication"},{"label":"BAYER YAKUHIN, Ltd","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Vomiting","drugRate":"52.7%","severity":"common","organSystem":""},{"effect":"Increased systolic blood pressure","drugRate":"","severity":"common","organSystem":""},{"effect":"Mild transient increases in serum potassium","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Thromboembolism (suspected)","drugRate":"6.7%","severity":"serious"},{"effect":"Seizures","drugRate":"3.6%","severity":"serious"},{"effect":"Severe hypertension","drugRate":"1.8%","severity":"serious"},{"effect":"Worsening CKD","drugRate":"34.5%","severity":"serious"},{"effect":"Declining quality of life","drugRate":"34.5%","severity":"serious"},{"effect":"Abdominal mass","drugRate":"1.8%","severity":"serious"}]},"trials":[],"aliases":[],"company":"BAYER YAKUHIN, Ltd","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MOLIDUSTAT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:06:53.251742+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:07:08.580092+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:06:58.813832+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOLIDUSTAT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:06:59.132685+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Egl nine homolog 3 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:00.230330+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3646118/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:06:59.890306+00:00"}},"allNames":"musredo","offLabel":[],"synonyms":["molidustat","molidustat sodium","musredo","BAY 85-3934"],"timeline":[{"date":"2021-01-22","type":"positive","source":"DrugCentral","milestone":"PMDA approval (BAYER YAKUHIN, Ltd)"}],"aiSummary":"Molidustat (Musredo), marketed by Bayer Yakuhin, Ltd., is a renal anemia treatment that has secured a position in the competitive landscape of anemia management. Its key strength lies in its mechanism of action, which involves inhibiting the Egl nine homolog 1 enzyme to regulate erythropoiesis, offering a novel approach to treating renal anemia. The primary risk is the competition from daprodustat, which was FDA-approved on February 1, 2023, and is patent-protected until March 13, 2038.","brandName":"Musredo","ecosystem":[{"indication":"Renal anemia","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Egl nine homolog 1","targets":[{"gene":"EGLN1","source":"DrugCentral","target":"Egl nine homolog 1","protein":"Egl nine homolog 1"},{"gene":"EGLN3","source":"DrugCentral","target":"Egl nine homolog 3","protein":"Egl nine homolog 3"},{"gene":"EGLN2","source":"DrugCentral","target":"Egl nine homolog 2","protein":"Egl nine homolog 2"},{"gene":"HIF1AN","source":"DrugCentral","target":"Hypoxia-inducible factor 1-alpha inhibitor","protein":"Hypoxia-inducible factor 1-alpha inhibitor"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Musredo exerts its effects by inhibiting the activity of Egl nine homolog 1, a key regulator of the hypoxia-inducible factor (HIF) pathway, which is essential for erythropoiesis and iron metabolism."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5486","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MOLIDUSTAT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOLIDUSTAT","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T02:43:28.043134","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:07:08.580179+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"daprodustat","drugSlug":"daprodustat","fdaApproval":"2023-02-01","patentExpiry":"Mar 13, 2038","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"molidustat","indications":{"approved":[{"name":"Renal anemia","source":"DrugCentral","snomedId":234348004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"daprodustat","brandName":"daprodustat","genericName":"daprodustat","approvalYear":"2023","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT04899661","phase":"","title":"A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-08-06","conditions":["Renal Anemia"],"enrollment":1081,"completionDate":"2027-09-30"},{"nctId":"NCT03543657","phase":"PHASE3","title":"Maintenance Treatment of Renal Anemia in Dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-23","conditions":["Anemia","Renal Insufficiency, Chronic"],"enrollment":229,"completionDate":"2019-12-24"},{"nctId":"NCT03418168","phase":"PHASE3","title":"A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-22","conditions":["Anemia","Renal Insufficiency, Chronic"],"enrollment":51,"completionDate":"2019-07-29"},{"nctId":"NCT03351166","phase":"PHASE3","title":"A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-01-22","conditions":["Anemia","Renal Insufficiency, Chronic"],"enrollment":25,"completionDate":"2018-11-20"},{"nctId":"NCT03350321","phase":"PHASE3","title":"A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-12","conditions":["Anemia","Renal Insufficiency, Chronic"],"enrollment":162,"completionDate":"2019-10-11"},{"nctId":"NCT03350347","phase":"PHASE3","title":"A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-13","conditions":["Anemia","Renal Insufficiency, Chronic"],"enrollment":164,"completionDate":"2019-11-28"},{"nctId":"NCT01318551","phase":"PHASE1","title":"Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-03-16","conditions":["Anemia"],"enrollment":56,"completionDate":"2014-08-14"},{"nctId":"NCT02312973","phase":"PHASE1","title":"To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-01-14","conditions":["Renal Insufficiency, Chronic"],"enrollment":40,"completionDate":"2016-06-01"},{"nctId":"NCT01975818","phase":"PHASE2","title":"Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10-28","conditions":["Anemia","Renal Insufficiency, Chronic"],"enrollment":201,"completionDate":"2015-12-15"},{"nctId":"NCT02064426","phase":"PHASE2","title":"Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-13","conditions":["Anemia","Renal Insufficiency, Chronic"],"enrollment":88,"completionDate":"2016-11-16"},{"nctId":"NCT02021409","phase":"PHASE2","title":"Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-01-28","conditions":["Anemia","Renal Insufficiency, Chronic"],"enrollment":126,"completionDate":"2015-11-23"},{"nctId":"NCT02055482","phase":"PHASE2","title":"Long-term Pre-dialysis Extension in Europe and Asia Pacific","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06-24","conditions":["Anemia","Renal Insufficiency, Chronic"],"enrollment":166,"completionDate":"2016-12-12"},{"nctId":"NCT01679587","phase":"PHASE1","title":"Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-09","conditions":["Kidney Diseases"],"enrollment":49,"completionDate":"2013-07"},{"nctId":"NCT01332942","phase":"PHASE1","title":"Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-04","conditions":["Anemia"],"enrollment":44,"completionDate":"2013-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"9JH486CZ13","INN_ID":"9655","RXNORM":"2637534","UMLSCUI":"C4078705","chemblId":"CHEMBL3646118","ChEMBL_ID":"CHEMBL3646118","KEGG_DRUG":"D11273","DRUGBANK_ID":"DB15642","PDB_CHEM_ID":"A1H","PUBCHEM_CID":"59603622","IUPHAR_LIGAND_ID":"8456","SECONDARY_CAS_RN":"1375799-59-9","MESH_SUPPLEMENTAL_RECORD_UI":"C000603972"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"BAYER YAKUHIN, Ltd","relationship":"Current Owner"}],"publicationCount":72,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan 21","pmid":"41742566","title":"Effectiveness and long-term safety of repeated oral administrations of molidustat in the management of anemia associated with chronic kidney disease in cats.","journal":"Journal of veterinary internal medicine"},{"date":"2026 Feb 20","pmid":"41721214","title":"EXPRESS: Palatability of sunflower oil-based versus aqueous verum formulations of molidustat in healthy cats.","journal":"Journal of feline medicine and surgery"},{"date":"2025 Nov 17","pmid":"41249974","title":"Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis.","journal":"BMC nephrology"},{"date":"2025 Nov 14","pmid":"41239296","title":"Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes.","journal":"BMC nephrology"},{"date":"2025 Oct","pmid":"41051985","title":"Clinical therapeutics in feline medicine: updates for old and new drugs.","journal":"Journal of feline medicine and surgery"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"BAYER YAKUHIN, Ltd","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:07:08.580179+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}